Abstract: The invention provides emulsion compositions that include a hydrophobic compound and an arylboronic acid. An exemplary emulsion comprises a hydrophobic polymer and a halogenated arylboronic acid. Use of an arylboronic acid provides the emulsion with exceptional stability. The stability provides advantages for the formation of articles formed from the emulsion, including microparticles, as well as other implantable or injectable medical articles having polymeric matrices.

Abstract: The present invention relates to a surfactant composition, consisting of 70 wt %-99.9 wt % sophorolactone, 0-1 wt % sophorolipid acid, less than 0.1% residual substrate, and remainder water. The invention further relates to products comprising this composition or hydrolysates thereof. The invention also relates to uses of these products and hydrolysates.

Abstract: Provided is an adhesion preventing medical material including a bioresorbable base material and a polyhydric alcohol or aqueous polyhydric alcohol solution, which contains the polyhydric alcohol, held in the bioresorbable base material. The bioresorbable base material includes a bioresorbable material, and has a swelling degree of 200 to 3,000 mass % and a water elution rate of not higher than 10 mass %. After immersed for 3 hours in water of 25° C. in an amount at least 50 times a total mass of the aqueous polyhydric alcohol solution or aqueous polyhydric alcohol solution and the bioresorbable base material, the polyhydric alcohol remains in an amount of not greater than 30 mass % of that of the polyhydric alcohol before the immersion.

Abstract: This invention relates to a cross-linkable chitosan composition comprising chitosan having a degree of deacetylation between 30 and 75%, wherein the chitosan is randomly deacetylated, and a cross-linking agent, wherein the molar ratio of the cross-linking agent to chitosan is 0.2:1 or less based on the number of functional groups in the cross-linking agent and the number of accessible amino groups in the chitosan. The invention also provides a chitosan hydrogel formed therefrom and uses thereof.

Abstract: The present invention provides the use of a composition comprising non-digestible oligosaccharide for the manufacture of a composition for enteral administration to an infant delivered via caesarean section.

Abstract: [Problems to be solved] In an oily cosmetic product using a filling extrusion container which is used by extruding a filling from a cylindrical storage portion to a tip of ejection portion, an oily cosmetic having smooth usability, excellent makeup durability and temperature stability, and good ejection performance is provided. [Solution] The present invention is an oily cosmetic and an oily cosmetic product. The oily cosmetic is filled and stored in a filling extrusion container, which is used by extruding a filling from a filling storage portion to the tip of ejection portion. The oily cosmetic includes (a) dextrin palmitate of 5 to 40 weight %, where the dextrin palmitate has acyl group substitution degree of less than 2.0, and (b) volatile hydrocarbon oil of 15 to 65 weight %.

Abstract: A process for making cross-linked polysaccharide gels, particularly cross-linked hyaluronic acid gels, under basic conditions. The resulting gels possess improved degradation characteristics, and are useful in a variety of medical and cosmetic applications.

Abstract: Provided herein are hydrogels and hydrogel-forming compositions that are useful for, among others, tissue regeneration in vivo. Methods for generating such hydrogels, for example, from such hydrogel-forming compositions are also provided herein. Therapeutic methods employing hydrogels and hydrogel-forming composition, for example, for restoration of tissue perfusion in the context of acute ischemia, are also provided. The disclosure also describes kits comprising components useful for generating hydrogels as described herein.

Abstract: The present disclosure relates to a deacetylation hydrolase of a hyaluronic acid a hyaluronic acid deacetylated by same and a derivative thereof. The deacetylated hyaluronic acid and the derivative thereof have the following characteristic: a delayed initial decomposition rate on a living body; minimized decrease of molecular weight and viscosity; accelerated gelation due to a lower gelation temperature than the gelation temperature for a non-deacetylated hyaluronic acid; and an hMSC survival rate that is hardly affected by increased concentration of the deacetylated hyaluronic acid and the derivative thereof in a culture medium. As a result, the deacetylated hyaluronic acid and the derivative thereof can be useful as a bioingredient such a delivery system for a cell, gene, drug, and the like, or a support for tissue engineering, etc.

Abstract: The invention provides an injectable formulation that includes an active agent; a biocompatible solvent system, crosslinkable polymers such as polysaccharides; and crosslinking agents; wherein the formulation is substantially free of water. The invention also provides a drug delivery depot formed from the injectable formulation wherein the polymers crosslink in the presence of water in the body of a patient, or in the air, prior to implantation in the patient. Also provided are methods of treatment using such formulations and drug delivery systems.

Abstract: Disclosed is a three-phase emulsion comprising an aqueous-gel outer phase; and a water-in-oil inner phase, wherein the emulsion is stable. The aqueous-gel outer phase can include 10% to 50% by weight of the total weight of the emulsion. This phase can also include 70% to 95% by weight of water based on the total weight of the aqueous-gel outer phase, a gelling agent, and an emulsifier having a hydrophilic-lipophilic balance (HLB) value of 10 to 19. The water-in-oil inner phase can include 50% to 95% by weight based on the total weight of the three-phase emulsion. This phase can also include 50% to 80% by weight of water based on the total weight of the water-in-oil inner phase, 20% to 50% by weight of oil based on the total weight of the water-in-oil inner phase, and an emulsifier.

Abstract: The present invention is directed to the use of one or more rebaudioside C polymorphs, or stereoisomers thereof, to enhance the sweet taste of a flavoring, such as glucosylated steviol glycoside, rebaudioside A, ammoniated glycyrrhizin, neohespherdin dihydrochalcone or thaumatin.

Abstract: The invention provides a method for reducing aggregation and inhibiting flocculation of a macromolecule, such as a protein, under physiological conditions, by the addition of certain cyclodextrins (CDs). The invention also provides a method to minimize inflammation at the injection site during subcutaneous administration of a macromolecule and pharmaceutical formulations for such administration. Further the invention provides methods of treating a CD20 positive cancer or an autoimmune disease, comprising administering a humanized anti-CD20 antibody in a pharmaceutical formulation of the invention. The invention further provides an in vitro dialysis method to evaluate the ability of an excipient to reduce aggregation of an antibody or other macromolecule under physiological conditions.

Abstract: The present invention relates to solid dispersions including, but not limited to, co-processed carbohydrates with different solubilities and concentrations, which have a microcrystalline plate structure. The solid dispersions, excipient systems and formulations of the present invention are highly compactable and durable and when compressed into solid dosage forms demonstrate uniform densification, low friability at low pressures, and and/or relatively constant low disintegration times at various hardnesses. The solid dosage forms of the present invention demonstrate superior organoleptics, disintegration, and/or robustness.

Abstract: The invention provides a particulate composition adapted for forming a bone graft substitute cement upon mixing with an aqueous solution, including i) a calcium sulfate hemihydrate powder having a bimodal particle distribution and a median particle size of about 5 to about 20 microns, wherein the calcium sulfate hemihydrate is present at a concentration of at least about 70 weight percent based on the total weight of the particulate composition; ii) a monocalcium phosphate monohydrate powder; and iii) a ?-tricalcium phosphate powder having a median particle size of less than about 20 microns. Bone graft substitute cements made therefrom, a bone graft substitute kit comprising the particulate composition, methods of making and using the particulate composition, and articles made from the bone graft substitute cement are also provided.

Abstract: The present invention is directed to topical compositions, comprising isoflavone nanoparticle compositions. The isoflavone nanoparticle compositions contain isoflavone in the form of nanoparticles and preferably a carrier. In the topical compositions recrystallization of the isoflavone to bigger particles is avoided.

Abstract: The present invention relates to a personal care composition comprising at least one sucrose fatty acid ester and at least one nonionic surfactant, wherein the composition is substantially free of silicone emulsifiers. The personal care compositions are particularly suitable for conditioning and moisturization applications.

Abstract: A personal care composition in the form of an oil-in-water emulsion comprising at least one sucrose fatty acid ester and at least one nonionic surfactant, said composition having a soaping index of less than about 2. The compositions are suitable for conditioning and moisturizing applications, and are optionally substantially free of silicone emulsifiers.

Abstract: Disclosed are compositions comprising crosslinked hyaluronic acid gels, preferably vinyl sulfone cross-linked hyaluronic acid known as hylan B gel, for use in topical cosmetic and dermatological formulations. The hylan B gel in these formulations provides prolonged delivery of incorporated substances to the surface of the skin, to provide a hydrated film on the surface of the skin, and to provide a substantive and compatible film on the skin.

Abstract: The purpose of the invention of the present application is to a method for preparing a hydrogel composed substantially only of nucleic acids. The invention of the present application provides: a nucleic acid sol-like composition for producing a nucleic acid gel without requiring the use of any nucleic acid ligase, wherein the composition comprises at least two nucleic acid monomers which are partly complementary to each other and are independently selected from the group consisting of a nucleic acid, a nucleic acid derivative, a modified nucleic acid, a compound capable of binding to a nucleic acid in complementary manner and a mixture thereof, one of the nucleic acid monomers has a moiety that constitutes a cohesive protruding end and a complementary nucleotide sequence moiety that can bind to at least one of the other nucleic acid monomers to form a double strand, and the composition contains no nucleic acid ligase; and a nucleic acid gel produced using the composition.

Abstract: A liquid composition that includes at least one steviol glycoside dissolved in glycerol, and a method for preparation thereof, preferably at a temperature above 100° C. The steviol glycoside is extracted from Stevia rebaudiana plant leaves. The steviol glycoside may include rebaudioside A, rebaudioside B, rebaudioside C, rebaudioside D, rebaudioside E, rebaudioside F, dulcoside A, steviol, stevioside, and/or steviolbioside. The relative concentration by weight of the rebaudioside A may be at least approximately 95%. The relative concentration by weight of the glycerol may be at least 70%. The liquid composition may further include additional ingredients, such as vitamins, minerals, extracts, preservatives, and/or other food additives. A dropper may be used for extracting individual drops of the liquid composition, such as into a beverage. The liquid composition may be used as a food additive, a sweetener, and/or a dietary supplement.

Abstract: Gastric resistant film-forming compositions are described herein. The composition comprises a gastric resistant natural polymer, a film-forming natural polymer, and optionally a gelling agent. Suitable gastric resistant natural polymers include polysaccharides such as pectin and pectin-like polymers. The film-forming composition can be used to prepare soft or hard shell gelatin capsules which can encapsulate a liquid or semi-solid fill material or a solid tablet (Softlet®) comprising an active agent and one or more pharmaceutically acceptable excipients. Alternatively, the composition can be administered as a liquid with an active agent dissolved or dispersed in the composition. The compositions are not only gastric resistant but may also prevent gastric reflux associated with odor causing liquids, such as fish oil or garlic oil, encapsulated in a unit dosage form and esophageal irritation due to the reflux of irritant drugs delivered orally.

Abstract: A combination product including at least one filler product and at least at least one bioresorbable and biodegradable silica-based material, for treating incontinence or treating aging of the skin and scars. Also, a composition including, in a physiologically acceptable medium, at least one filler product and at least at least one bioresorbable and biodegradable silica-based material.

Abstract: A kit for forming a bioerodible composition is provided with a first aliquot portion of a reaction mixture having an aldehydic polymer solution, and a second aliquot portion of a reaction mixture having solids which include a cross-linking hydrazide. When mixed, the first and second aliquot portions of the reaction mixture react at a pH of 4 to 6 to form a solidified bioerodible composition within about 1 to about 10 minutes, to form a hydrazide cross-linked aldehydic polymer matrix. The bioerodable composition may be usefully employed to seal and/or treat wounds (e.g., a surgical incision).

Abstract: The present invention relates to elastic, hydrophilic and substantially spherical microspheres useful for dermal augmentation and tissue bulking. The invention provides injectable compositions comprising the microspheres and a biocompatible carrier for use in dermal augmentation. The present invention further provides methods of dermal augmentation and tissue bulking, particularly for the treatment of skin contour deficiencies, Gastro-esophageal reflux disease, urinary incontinence, and urinary reflux disease, using the injectable compositions.

Abstract: An injectable device useful for facial sculpting and correction of facial features, for example, for augmenting the chin in a human being is provided, the device being made of a composition comprising a hyaluronic acid crosslinked with a multifunctional polyethylene glycol (PEG)-based crosslinking agent.

Abstract: In a first aspect, the invention provides a polymeric nanoparticle comprising at least one polycationic polymer; at least one polyanionic polymer; and a therapeutically effective amount of at least one therapeutic agent. In a second aspect, the invention provides a method for the preparation of a polymeric nanoparticle according to the first aspect; the method comprising the steps of: (i) admixing the at least one polyanionic polymer with the at least one therapeutic agent; and (ii) introducing to the mixture of (i), to the at least one polycationic polymer. In a third aspect, the invention provides a polymeric nanoparticle according to the first aspect of the present invention, or a polymeric nanoparticle prepared according to the second aspect of the present invention; for use in the treatment of an inflammatory and/or arthritic disorder caused by or associated with dysfunctional nuclear receptor signalling.

Abstract: Provided are personal care compositions comprising a first surfactant comprising sodium lauryl sulfate and a second surfactant having a structure represented by wherein each a has a value of about 1 to about 110, b has a value of about 16 to about 70, and at least one R group is SO3, and the other R group is SO3 or hydrogen. Also provided are methods of producing personal care compositions and methods of ameliorating skin or mucosal membrane irritation due to sodium lauryl sulfate.

Abstract: The invention relates to a combined pharmaceutical composition or pharmaceutical preparation, comprising a first component containing a first ligand for a polyspecific lectin in a reticuloendothelial cell and a second component containing a carrier, a labeling agent, or a medicament for treating a disease associated with a target cell, each of which is targeted by a second ligand for a polyspecific lectin in a reticuloendothelial cell different from the first ligand, and also relates to a method for labeling a target cell and a method for treating a disease associated with a target cell, each using the same.

Abstract: In exemplary implementations of this invention, hierarchical, nanometer-precise assembly is performed: A first structural unit is attached to a solid substrate in a first fluidic flow. A second structural unit is attached to the first structural unit in a second fluidic flow, a third structural unit is attached to the second structural unit in a third fluidic flow, and so on, until a target structure comprising the structural units is assembled. The first, second, third and so on fluidic flows are separate and occur in order in a temporal sequence. During the temporal sequence, a specific permutation of nucleobases is used repeatedly, in separate fluidic flows which occur at different times, to form multiple attachments between structural units in an assembly. The assembled target structure is removed from the solid substrate. Attachments between the structural units may be formed by nucleobase pairing.

Abstract: The present invention provides an infused carbohydrate based gel pad comprising: glucose polymer syrup, sugar, a hydrocolloid gelling agent, salt, acid, water and an infusing compound for oral transmucosal delivery wherein the gel pad (i) provides transmucosal delivery of active ingredients of the infusing compound into the bloodstream over a predetermined period of time; and (ii) possesses the property of adhesion to gum line tissue of an oral cavity and lack of adhesion to buccal tissue of the oral cavity. The present invention further provides a method of making the infused carbohydrate based gel.

Abstract: Methods for hydrolyzing solid ungranulated lysophosphatidylcholine with phospholipase A2 are provided. Also disclosed are methods for making a lipid matrix of lysophosphatidylcholine, monoglyceride and fatty acid, and lipid matrices of particular structure.

Abstract: A pearl sugar particle includes granulated sugar and at least one additive, wherein the at least one additive is distributed homogeneously throughout the pearl sugar particle. A composition including a plurality of pearl sugar particles and a process for preparing a pearl sugar are also disclosed.

Abstract: A method of preparing a mucoadhesive film formulation by preparing a film forming composition including lambda carrageenan as a film forming polymer, at a concentration of about 1-7% by weight, a plasticizer at a concentration of about 1-15% by weight, a biologically active substance, and purified water; distributing the film forming composition as a wet film layer onto a solid surface; and allowing the film layer to dry. A mucoadhesive film obtained by the method and a film dosage unit.

Abstract: Disclosed are drug delivery compositions comprising an oligonucleotide-modified nanoparticle and a therapeutic agent. Specifically, disclosed are compositions comprising a number of oligonucleotide molecules in a ratio to therapeutic agent molecules to allow a sufficient transportation of the therapeutic agent molecules into a cell. The therapeutic agents include both hydrophobic and hydrophilic. Different attachments of therapeutic agents in a composition are also described.

Abstract: According to the present invention, a substituted aromatic compound represented by the following general formula (I) is provided. In general formula (I), A1, A2, and A3 each independently represent an aryl group substituted by a hydrophilic group.

Abstract: The present invention is directed to the use of one or more rebaudioside C polymorphs, or stereoisomers thereof, to enhance the sweet taste of a flavoring, such as glucosylated steviol glycoside, rebaudioside A, ammoniated glycyrrhizin, neohespherdin dihydrochalcone or thaumatin.

Abstract: Disclosed herein is a fibrous tissue sealant in the form of an anhydrous fibrous sheet comprising a first component which is a fibrous polymer containing electrophilic or nucleophilic groups and a second component capable of crosslinking the first component when the sheet is exposed to an aqueous medium, thereby forming a crosslinked hydrogel that is adhesive to biological tissue. The fibrous tissue sealant may be useful as a general tissue adhesive for medical and veterinary applications such as wound closure, supplementing or replacing sutures or staples in internal surgical procedures, tissue repair, and to prevent post-surgical adhesions. The fibrous tissue sealant may be particularly suitable for use as a hemostatic sealant to stanch bleeding from surgical or traumatic wounds.

Abstract: Methods for delivering therapeutic agent(s) to the central nervous system to treat a first CNS-related disease and/or condition while avoiding systemic exposure for patients having a second concurrent non-CNS-related disease and/or condition wherein the presence of the second disease and/or condition contraindicates systemic administration of the therapeutic agent(s) and/or pharmaceutical compound to treat the first disease or condition. The present invention provides these advantages by applying the therapeutic agent(s) and/or pharmaceutical composition(s) to the upper third of the nasal cavity, thereby bypassing the blood-brain barrier and administering the therapeutic agent(s) and/or pharmaceutical compound(s) directly to the CNS.

Abstract: A method for the development of a library of modified sophorolipids using a wide-range of chemical and enzyme catalyst tools to identify modified sophorolipids that can be used in pure form, as mixtures with other modified sophorolipids, as mixtures with natural sophorolipids, as mixtures with modified and natural sophorolipids, and as mixtures with other compounds known by one skilled in the art for use in the dispersion, solubilization or emulsification of various oil types and nutraceuticals, and modified sophorolipids for use in dispersion, solubilization or emulsification processes.

Abstract: Stevia compositions are prepared from steviol glycosides of Stevia rebaudiana Bertoni. The compositions are able to provide a superior taste profile and can be used as sweetness enhancers, flavor enhancers and sweeteners in foods, beverages, cosmetics and pharmaceuticals.

Abstract: Disclosed is a lyophilized liposome composition encapsulating a water-soluble drug and a preparation process thereof. The lyophilized liposome composition comprises a water-soluble drug, a phospholipid, a polyethylene glycol-derivatized phospholipid, cholesterol and a lyoprotectant, wherein the lyoprotectant comprises a saccharide and a cyclodextrin or cyclodextrin derivative. The encapsulation rate of the lyophilized liposome composition encapsulating the water-soluble drug is ?90%.

Abstract: This application discloses cyclodextrin-modified materials for carrying drugs and other active agents, such as nucleic acids. Compositions are also disclosed of cyclodextrin-modified materials that release such active agents under controlled conditions. The invention also discloses compositions of cyclodextrin-modified polymer carriers that are coupled to biorecognition molecules for assisting the delivery of drugs to their site of action.

Abstract: Stents and delivery systems with reduced chemical degradation and methods of sterilizing the same are disclosed.

Abstract: Described is a lipid nanoparticle composition that includes a macromolecule conjugated to a polymer and a targeting agent. The composition can include a therapeutic agent. The therapeutic agent can be an antisense oligonucleotide (ASO). Exemplary ASOs are targeted to a portion of a nucleic acid encoding Akt-1, and which modulates the expression of Akt-1; or targeted to a portion of a nucleic acid encoding HIF-1, and which modulates the expression of HIF-1. Also described is a lipid nanoparticle composition that includes a macromolecule conjugated to a polymer and a therapeutic agent that is an ASO such as an ASO targeted to a portion of a nucleic acid encoding Akt-1, and which modulates the expression of Akt-1 or an ASO targeted to a portion of a nucleic acid encoding HIF-1, and which modulates the expression of HIF-1. Pharmaceutical formulations, methods of making the lipid nanoparticles, and methods of using the lipid nanoparticles, for example for treating cancers, are also disclosed.

Abstract: The present document describes a pharmaceutical composition as well as methods to improve organ function using a high dose of insulin and maintaining normal glycemia. Methods of intensive insulin therapy using the pharmaceutical composition are also described.

Abstract: The present invention relates to a trehalose fatty acid ester composition, including a trehalose fatty acid ester, wherein all the fatty acid residues held by all the trehalose fatty acid esters in the composition are saturated fatty acid residues having 8 to 22 carbon atoms, the composition contains at least two types of esters selected from the group consisting of a triester, a tetraester, a pentaester, a hexaester, a heptaester, and an octaester, and the sum amount of the esters relative to the total amount of the trehalose fatty acid ester in the composition, is from 20 to 100% by area. According to the present invention, it is possible to provide a composition which has excellent thermostability and an excellent effect of adjusting the hardness for various types of waxes, and which can be used as a solidifier together with a wax for various types of cosmetics.

Abstract: The subject invention is directed to a pharmaceutical composition comprising an open matrix network carrying a pharmaceutically active ingredient, wherein the open matrix network comprises levan.

Abstract: An object of the present invention is to provide a glucosamine-containing glucan, a modified product and a conjugate thereof. The glucosamine-containing glucan of the present invention is a glucosamine-containing glucan wherein the glucan has a plurality of non-reducing ends and at least one glucosamine residue is bound via an ?-1,4-bond to each of two or more non-reducing ends of the branched ?-1,4-glucan, but no glucosamine residue is present at a position other than the non-reducing ends of the branched ?-1,4-glucan, wherein the degree of polymerization of the glucan is 15 or more and 4×105 or less. The glucosamine-containing glucan of the present invention can be provided by allowing an ?-glucan phosphorylase to act on an aqueous solution comprising a branched ?-1,4-glucan and glucosamine-1-phosphate.

Abstract: The present invention is directed to a controlled release solid dosage form comprising a controlled release modifier and an active ingredient comprising at least one of a pharmaceutical, veterinary, or nutraceutical active ingredient, wherein the controlled release modifier comprises lambda carrageenan from the taxonomic order Halymeniales. The present invention is also directed to ethanol resistant controlled release solid dosage forms and methods for reducing the ethanol sensitivity of an active ingredient in a controlled release solid dose form.